Elite Pharmaceuticals, Inc. (ELTP)

Market Cap	539.48M
Revenue (ttm)	71.17M
Net Income (ttm)	-6.39M
Shares Out	1.07B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	594,200
Average Volume	1,242,271
Open	0.500
Previous Close	0.490
Day's Range	0.500 - 0.510
52-Week Range	0.120 - 0.750
Beta	0.27
RSI	45.10
Earnings Date	Feb 13, 2025

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 64
• Stock Exchange: OTCMKTS
• Ticker Symbol: ELTP

Financial Performance

In 2023, Elite Pharmaceuticals's revenue was $56.63 million, an increase of 65.79% compared to the previous year's $34.16 million. Earnings were $20.11 million, an increase of 464.56%.